Brigatinib 180 mg works by specifically targeting and inhibiting the ALK gene mutation that drives the growth of ALK-positive metastatic NSCLC. By blocking this abnormal activity, Brigatinib 180 mg slows down or halts the progression of cancer, giving you a fighting chance to regain your health.